Di(Hydroxyethyl)Ether

Di(Hydroxyethyl)Ether

SCHEMBL15903151

CCCCC(CC)C(O)C(CC)CO.OCCOCCO

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 2/20 0.44
THRB P10828 1/20 0.44
LMNA P02545 4/20 0.41
ALDH1A1 P00352 3/20 0.38
USP2 O75604 2/20 0.36
MAPK1 P28482 2/20 0.34
CYP3A4 P08684 3/20 0.32
CASP1 P29466 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SLCO1B3 Q9NPD5 1/20 0.32
SLCO1B1 Q9Y6L6 1/20 0.32
CYP2D6 P10635 2/20 0.30
MMP9 P14780 1/20 0.30
MMP8 P22894 1/20 0.30
MMP14 P50281 1/20 0.30
SPHK1 Q9NYA1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49315 0.87 LMNA (0.52) HTTMAPTLMNAALDH1A1MAPK1
SCHEMBL11507467 0.80 MEN1 (0.42) TSHRMEN1KMT2AHTTMAPT
SCHEMBL14125822 0.79 ALDH1A1 (0.44) TSHRLMNAALDH1A1MAPK1CYP3A4
SCHEMBL15903153 0.79 MEN1 (0.44) TSHRMEN1KMT2AHTTMAPT
SCHEMBL11237297 0.77 ALDH1A1 (0.42) TSHRMEN1KMT2ALMNAALDH1A1
SCHEMBL14125514 0.77 ALDH1A1 (0.42) TSHRLMNAALDH1A1MAPK1CYP3A4
Di(Hydroxyethyl)Ether SCHEMBL28126799 0.75 TSHR (0.62) TSHRMEN1KMT2AHTTMAPT
Tetraethylene Glycol SCHEMBL9246525 0.75 LMNA (0.70) TSHRMEN1KMT2AHTTMAPT
SCHEMBL31215136 0.75 MEN1 (0.47) TSHRMEN1KMT2AHTTMAPT
SCHEMBL21840395 0.75 MEN1 (0.52) TSHRMEN1KMT2AHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3253583-B1 THERMAL MANAGEMENT MATERIALS CONTAINING PHASE CHANGE MATERIALS LATENT HEAT SOLUTIONS LLC (US) 2023-11-29 EP disclosed
WO-2016126815-A1 THERMAL MANAGEMENT FILMS CONTAINING PHASE CHANGE MATERIALS Outlast Technologies, LLC (US) 2016-08-11 WO disclosed
US-20160223269-A1 THERMAL MANAGEMENT FILMS CONTAINING PHASE CHANGE MATERIALS LATENT HEAT SOLUTIONS, LLC 2016-08-04 US disclosed
EP-2948459-A1 NEW RADIATION-CURABLE COMPOUNDS AND COATING COMPOSITIONS BASF SE (DE) 2015-12-02 EP disclosed
WO-2014114534-A1 NEW RADIATION-CURABLE COMPOUNDS AND COATING COMPOSITIONS BASF SE (DE) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160223269-A1 THERMAL MANAGEMENT FILMS CONTAINING PHASE CHANGE MATERIALS TRRAP, POLM, PARG TSHR 4291/4885MEN1 1187/4885KMT2A 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.